R&D Leaders' Forum Autumn 2002
Presentations
If you would like to purchase the documentation (Only available on CD) please email team@phacilitate.co.uk and we will confirm a price with you.
PRE-CONFERENCE BRIEFING:
Defining the successful R&D business model of the future
Kenneth I. Kaitin, Ph.D
Chairman’s introduction: Is your business model sustainable?
Jo Walton
Financial analyst perspective: What is the financial community’s view of big pharma performance at present? How can the industry increase value for its shareholders?
Richard de Souza
Implementing strategies to overcome the key challenges and to capitalise on the opportunities offered by the dynamic external environment
FOCUS SESSION 1
OPTIMISING THE INFLUENCE OF PORTFOLIO SELECTION AND MANAGEMENT ON R&D
Dr Rafael Bengoa
in the developed world?
Dr Nahed Ahmed
Best practices in portfolio management and benefits of integrating it across the organisation as a whole. How can these be maximised?
Dr Richard M. Bayney
Failing fast - managing R&D risks across different therapeutic areas. Can we afford to use the same metrics and stage-gate processes?
FOCUS SESSION 2
WHICH BUSINESS MODEL IS MOST EFFECTIVE AT INCREASING RESEARCH PRODUCTIVITY?
Dr Garth Rapeport
Re-designing the corporate R&D model - exploring the benefits of creating internal competition within the organisation
Dr Allan Marchington
Defining the key strategic drivers behind the formation of a ‘pharmaceutical organisation of the future?’
Dr Michael H. Tarbit
Design before synthesis: Integrating modern technologies into new discovery paradigms
FOCUS SESSION 3
INTEGRATING COMPETITIVE INTELLIGENCE INTO R&D TO GAIN ADVANTAGE IN THE MARKET PLACE
Dr Ben Gilad
Early warning programs: Can R&D leaders go blind?
Dick Klavans
Examining science strategy
Andrew Garman
Case Study: Scenarioing, continuous strategy, and strategic early warning for discovery
AFTERNOON PLENARY SESSION
Dr Colin Greengrass
Panellists:
Iain Buchanan
Roundtable discussion: Big pharma should not maintain a research department in the traditional sense. Discuss
Moderator:
MAIN CONFERENCE DAY 1:
Integrated strategies to increase R&D productivity
Dr Steve Arlington
KEYNOTE ADDRESS
2010 – The threshold of innovation
Dirk Heyman and
Christian Florkemeier
The new network (smart objects) and its potential for pharmaceutical companies.
FOCUS SESSION 1
IMPROVING QUALITY AND DECISION-MAKING AT THE LEAD SELECTION AND VALIDATION STAGES
Dr Kimber G. Hardy
Optimising early-stage decision-making
Dr Seth Pinsky
Design and practical implementation of an informatics platform to integrate, manage and exploit the key data elements, information and processes required for effective lead selection and optimisation
Dr Daniel F. Wyss
Structure-based approaches for lead discovery and optimisation
Dr Alan G. E. Wilson
Integrating predictive ADME and toxicity modelling with high-throughput screening
Professor Robert Glen
Workshop: High-throughput screening – has it worked, or does a more cerebral approach bring results of a higher quality?
FOCUS SESSION 2
REMOVING THE KEY BARRIERS TO THE ACCELERATION OF DEVELOPMENT. HOW DOES THE CLINICAL MODEL NEED TO CHANGE TO INCREASE PRODUCTIVITY?
Dr Ian Hudson
Addressing key areas of regulatory concern for the industry
Henrik Schou
How can real-time data collection systems accelerate the clinical process?
Andreas Pangerl, MD
Case Study: Optimising investigator management to enable rapid commencement of a mega trial
FOCUS SESSION 3
DEVELOPING YOUR HUMAN CAPITAL AND ORGANISATIONAL STRATEGIES
Andrew Scott
Rising to the challenge of placing scientific, research-based personnel in a manufacturing paradigm
Lucy Knight
First steps on a change journey
MAIN CONFERENCE DAY 2:
Integrating all aspects of R&D – the key to unlocking R&D productivity?
Dr Victor Newman
KEYNOTE ADDRESS
Overcoming the major barriers to an integrated approach to managing R&D knowledge for enhanced productivity
François Mandeville
Enable fast scientific decision-making by supporting information synthesis, collaboration and the bridging of diverse scientific domains
FOCUS SESSION 1
EXPLOITING GENOMIC AND PROTEOMIC TECHNOLOGY TO GET LEADS TO THE CLINIC FASTER
Dr Mike Stapleton
Accelerating Drug Discovery: Introducing Discovery Studio
FOCUS SESSION 2
INTEGRATED SOLUTIONS TO ACHIEVE BREAKTHROUGH PRODUCTIVITY IMPROVEMENT IN DRUG DEVELOPMENT. OPTIMISING THE ROLE OF IN SILICO MODELLING TECHNOLOGIES
Simon Hughes
Integrating scientific, clinical, commercial and financial information to maximise the value of your clinical trials
John Robson –
spoke for Jo Webber
The three keys to increasing drug development productivity
Dr Jean-Michel Gries
Case study: Building integrated simulation models, incorporating clinical response and marketing research to provide realistic, market-sensitive recommendations for decision making in drug development
FOCUS SESSION 3
RECONCILING THE INDUSTRIALISATION OF DISCOVERY WITH THE NEED TO OPTIMISE CREATIVITY AND TARGET QUALITY IN ORDER TO MAXIMISE RETURN ON YOUR INVESTMENT
Dr Wilma W. Keighley
Moderator’s introduction
